-
41.发明公开Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction 审中-公开化合物作为突变CFTR蛋白的调节剂及其对疾病与CFTR蛋白功能障碍相关的治疗用途
公开(公告)号：EP2826771A3
公开(公告)日：2015-02-18
申请号：EP14185330.9
申请日：2011-06-20
发明人： Odolczyk, Norbert , Zielenkiewicz, Piotr , Wieczorek, Grzegorz , Edelman, Aleksander , Tondelier, Danielle , Fritsch, Janine
IPC分类号： C07D219/10 , C07D473/30 , C07F9/30 , C07C233/65 , A61K31/663 , A61K31/435 , A61K31/522 , A61K31/194 , A61P11/00 , C07D401/12 , C07C235/84 , C07D473/22
CPC分类号： A61K31/194 , A61K31/496 , A61K31/52 , A61K31/663 , C07C233/65 , C07C235/84 , C07C2603/18 , C07D219/10 , C07D401/12 , C07D473/22 , C07D473/30 , C07F9/304 , C07F9/305
摘要： The present invention relates to novel protein modulators capable of altering function of the mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction. The invention provides compositions, pharmaceutical preparations and methods of correcting the cellular alteration of a mutant CFTR protein wherein the CFTR mutation is a mutation ΔF508-CFTR, or another mutation of class II.
摘要翻译： 本发明涉及一种能够改变突变体CFTR蛋白的功能和它们用于治疗与CFTR蛋白故障有关的疾病的使用新颖蛋白调节剂。 本发明提供了组合物，药物制剂和校正的突变CFTR蛋白worin的CFTR突变的细胞改变是突变“F508-CFTR，或II类的另一突变的方法。
-
42.发明公开Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction 审中-公开化合物作为突变CFTR蛋白调制器和它们用于疾病治疗的蛋白质CFTR障碍有关
公开(公告)号：EP2816035A2
公开(公告)日：2014-12-24
申请号：EP14185333.3
申请日：2011-06-20
发明人： Odolczyk, Norbert , Zielenkiewicz, Piotr , Wieczorek, Grzegorz , Edelman, Aleksander , Tondelier, Danielle , Fritsch, Janine
IPC分类号： C07D219/10 , C07D473/30 , C07F9/30 , C07C233/65 , A61K31/663 , A61K31/435 , A61K31/522 , A61K31/194 , A61P11/00 , C07D401/12 , C07C235/84 , C07D473/22
CPC分类号： A61K31/194 , A61K31/496 , A61K31/52 , A61K31/663 , C07C233/65 , C07C235/84 , C07C2603/18 , C07D219/10 , C07D401/12 , C07D473/22 , C07D473/30 , C07F9/304 , C07F9/305
摘要： The present invention relates to novel protein modulators capable of altering function of the mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction. The invention provides compositions, pharmaceutical preparations and methods of correcting the cellular alteration of a mutant CFTR protein wherein the CFTR mutation is a mutation ΔF508-CFTR, or another mutation of class II.
-
公开(公告)号：EP2700638A1
公开(公告)日：2014-02-26
申请号：EP13001957.3
申请日：2007-04-23
IPC分类号： C07D473/04 , C07D473/16 , C07D473/18 , C07D473/20 , C07D473/22 , C07D473/24 , C07D473/26 , C07D473/28 , C07D473/30 , C07D473/32 , C07D473/34 , C07D473/36 , C07D473/38 , A61K31/52 , A61K31/522 , A61P35/00 , A61P37/00 , A61P31/00
CPC分类号： A61K47/48046 , C07D473/18
摘要： The present invention provides a new patentable class of purine analog compounds, as well as compositions and methods of using them, for example, to prevent or treat various diseases and disorders in human and non-human animals.
摘要翻译： 本发明提供了一种新的可专利类嘌呤类似物类化合物，以及使用它们的组合物和方法，例如预防或治疗人和非人动物中的各种疾病和病症。
-
公开(公告)号：EP2029597A4
公开(公告)日：2011-11-23
申请号：EP07755916
申请日：2007-04-23
申请人： UNIV CALIFORNIA
IPC分类号： C07D473/04 , A61K31/52 , A61K31/522 , A61P31/00 , A61P35/00 , A61P37/00 , C07D473/16 , C07D473/18 , C07D473/20 , C07D473/22 , C07D473/24 , C07D473/26 , C07D473/28 , C07D473/30 , C07D473/32 , C07D473/34 , C07D473/36 , C07D473/38
CPC分类号： A61K47/48046 , C07D473/18
-
公开(公告)号：EP2010535A4
公开(公告)日：2011-07-20
申请号：EP07748015
申请日：2007-04-12
申请人： ASTRAZENECA AB
发明人： TIDEN ANNA-KARIN , VIKLUND JENNY
IPC分类号： C07D473/22 , H01L31/04 , A61K31/52 , A61K31/522 , A61P9/10 , A61P11/08 , A61P25/16 , C07D473/20 , H01R4/00 , H01R4/16
CPC分类号： C07D473/20 , C07D473/22
-
46.发明公开Use of thioxanthine derivatives as MPO inhibitors 审中-公开Verwendung von Thioxanthinderivaten als MPO Hemmer
公开(公告)号：EP2332541A1
公开(公告)日：2011-06-15
申请号：EP10170768.5
申请日：2003-04-15
申请人： AstraZeneca AB
IPC分类号： A61K31/522 , C07D473/22
CPC分类号： A61K31/522 , C07D473/22
摘要： A compound of formula (Ia) or (Ib)
wherein X is S; Y is O; R 2 is C1 to 6 alkyl substituted by C1 to 6 alkoxy; and R 1 R 3 and R 4 are all hydrogen, or a pharmaceutically acceptable salt thereof, the preparation of such compounds, compositions comprising such compounds, and the use of such compounds in the treatment of MPO mediated disease states.摘要翻译： 式（Ia）或（Ib）的化合物，其中X是S; Y是O; R 2为被C 1-6烷氧基取代的C 1-6烷基; 和R 1 R 3和R 4都是氢或其药学上可接受的盐，这些化合物的制备，包含这些化合物的组合物，以及这些化合物在治疗MPO介导的疾病状态中的用途。
-
公开(公告)号：EP2158202A1
公开(公告)日：2010-03-03
申请号：EP08762543.0
申请日：2008-06-11
申请人： AstraZeneca AB
IPC分类号： C07D473/22 , A61K31/522 , A61P25/16
CPC分类号： C07D473/22
摘要： The present invention relates tonovel crystalline forms of 3-(2R-tetrahydrofuryl-methyl)- 2-thioxanthine. Further the present invention also relates to compositions comprising them and their use in therapy.
-
公开(公告)号：EP2070930A1
公开(公告)日：2009-06-17
申请号：EP09151275.6
申请日：2000-11-13
申请人： Biogen Idec MA, Inc.
发明人： Kiesman, William F. , Dowling, James E. , Ensinger, Carol L. , Kumaravel, Gnanasambandam , Petter, Russel C. , Lin, Ko Chung , Chang, He Xi
IPC分类号： C07D473/22 , C07D473/06 , C07D519/00 , A61K31/52 , A61P9/00 , A61P25/28 , C07F9/6561 , C07D311/00 , C07D493/08 , C07D307/00
CPC分类号： C07D473/06 , C07D473/22 , C07F9/65616
摘要： The invention is based on the discovery that compounds of Formula (I) are unexpectedly highly potent and selective inhibitors of the adenosine A 1 receptor. Adenosine A 1 antagonists can be useful in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable. In one embodiment, the invention features a compound of formula (I).
摘要翻译： 本发明基于以下发现：式（I）的化合物是意想不到的高度有效和选择性的腺苷A 1受体抑制剂。 腺苷A 1拮抗剂可用于预防和/或治疗许多疾病，包括心脏和循环系统疾病，中枢神经系统的退行性疾病，呼吸系统疾病以及适合利尿治疗的许多疾病。 在一个实施方案中，本发明特征在于式（I）化合物。
-
公开(公告)号：EP2061793A2
公开(公告)日：2009-05-27
申请号：EP07811385.9
申请日：2007-08-17
申请人： Novacardia, Inc.
IPC分类号： C07D473/04 , C07D473/06 , C07D473/08 , C07D473/10 , C07D473/12 , C07D473/14 , C07D473/20 , C07D473/22 , A61K31/522 , A61K31/52 , A61P11/08 , A61P7/10
CPC分类号： C07D473/04 , C07D473/06
摘要： The present invention relates to certain compounds and to methods for the preparation of certain compounds that can be used in the fields of chemistry and medicine. Specifically, described herein are methods for the preparation of various compounds and intermediates, and the compounds and intermediates themselves. More specifically, described herein are methods for synthesizing KW-3902 derivatives of Formula (I), (II), (HI), (IV), (V), and (VI).
-
公开(公告)号：EP1773826A2
公开(公告)日：2007-04-18
申请号：EP05763620.1
申请日：2005-07-01
申请人： Exelixis, Inc.
发明人： BANNEN, Lynne Canne , CHAN, Diva Sze-Ming , DALRYMPLE, Lisa Esther , JAMMALAMADAKA, Vasu , KHOURY, Richard George , LEAHY, James William , MAC, Morrison B. , MANN, Grace , MANN, Larry W. , NUSS, John M. , PARKS, Jason Jevious , WANG, Yong , XU, Wei
IPC分类号： C07D417/04 , C07D487/04 , C07D473/06 , C07D473/10 , C07D473/22 , C07D473/24 , C07D473/30 , C07D473/34 , C07D473/38 , C07D473/40 , C07D491/04 , C07D495/04 , A61K31/52 , A61K31/522 , A61K31/519 , A61K31/437 , A61K31/4365 , A61K31/4355 , A61P35/00
CPC分类号： C07D487/04 , C07D209/52 , C07D471/04 , C07D473/30 , C07D473/32 , C07D493/04 , C07D493/14 , C07D493/20 , C07D498/04
摘要： The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides appropriately functionalized 5,6-fused bicyclics which inhibit, regulate and/or modulate kinase receptor, particularly c-Met, KDR, and flt-3, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions.
-
-
-
-
-
-
-
-
-
搜索结果
78 条记录 (耗时 0.025 秒)
